KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Amortizatization of Intangibles (2024 - 2025)

Nektar Therapeutics (NKTR) has 2 years of Amortizatization of Intangibles data on record, last reported at -$1.4 million in Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles rose 30.57% year-over-year to -$1.4 million; the TTM value through Sep 2025 reached -$5.2 million, changed N/A, while the annual FY2024 figure was -$9.2 million, 37.77% up from the prior year.
  • Amortizatization of Intangibles reached -$1.4 million in Q3 2025 per NKTR's latest filing, down from -$869000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at -$869000.0 in Q2 2025 and bottomed at -$3.1 million in Q1 2024.